A randomised, controlled, non-inferiority design was considered most appropriate method to answer our stated aim. Where two treatments, have both previously been shown to be superior to a placebo, and/or in cases where the use of a placebo may be unethical or impractical, a non inferiority design can be used to determine if one treatment is "no worse" than the other[9, 10]. Usually, as in this study, the interventions include a new treatment and an active comparator, or a treatment currently in use. In relation to this trial, the single injection is the new treatment and the four injection technique is the active comparator. The null hypothesis is not proven if the measured effects of the two treatments lie within a specified non-inferiority margin [11].
Hypothesis
The null hypothesis is conventionally stated in an RCT which assumes that there is no difference between the intervention group and controls. The null hypothesis places the onus on the intervention to be proven [12]. The null hypothesis is accepted if it cannot be refuted at the a priori defined level of significance. However, a non-inferiority design is attempting to show that two active treatments are similar in effect [13]. Therefore, the null hypothesis cannot be rejected if the measured treatment effects lie within a pre-specified non-inferiority margin [11]. Within non-inferiority design the sample size must be robust enough to test the quantitative or clinically relevant margin or definition of non-inferiority [13]. This margin is informed by considerations of clinically relevance, with any treatment differences falling outside this range indicating that any dissimilarity between treatments is unacceptably large [9].
The predefined non-inferiority margin for the present study was defined by the minimal clinically (i.e. not statistically) significant difference in the Visual Analogue Scale (VAS) to measure self-reported pain. Therefore, the null hypothesis (H0) would be "treatment is inferior", the alternative hypothesis (HA) "treatment is non-inferior":
H0: Difference between the four injection intradermal SWI and single injection intradermal SWI is ≥ 1 cm on the 10 cm VAS
HA: Difference between the four injection intradermal SWI and single injection intradermal SWI is < 1 cm on the 10 cm VAS
Study site and population
The study population will be recruited from the Birth Suites of two major maternity hospitals. Women eligible for the study are those that request analgesia for continuous severe lower back pain during labour (≥7 on the VAS) and provide informed consent. The categorisation of severe back pain as ≥7 on the VAS has been previously validated [14] and consistent with defined inclusion criteria in previous SWI studies [14–17]. Women with a baseline VAS score of <7 were more likely to find administration of the procedure unacceptable [16].
The eligibility criteria are pre-specified as:
Inclusion criteria
Participants eligible for the study will be defined as:
Women at term (between 37 and 42 weeks)
Nulliparous or multiparous
Singleton pregnancy
Cephalic presentation
First stage labour (spontaneous or induced)
No previous analgesia pharmacological analgesia (nitrous oxide inhalation, narcotics)
Back pain assessed by VAS as ≥7
Ability to give informed consent. This may exclude women of non-English speaking backgrounds, where an interpreter is unavailable, and those women whose consent is required to be provided by a parent or guardian.
Exclusion criteria
Gestation <37 weeks
Multiple pregnancy
Malpresentation (Breech Transverse etc.)
Second stage labour
Pharmacological analgesia prior to SWI
Back pain assessed by VAS <7
Women whose labour would be considered high risk.
Interventions
Control group
Participants randomised to the control group will be given SWI using the standard four injection intradermal technique into the skin surrounding the Michaelis rhomboid over the sacral area. Anatomically, the injections will be administered: two over each posterior superior iliac spine (PSIS) and two three cm below and one cm medial to the PSIS (Figure 1). Minor discrepancies or changes to the anatomical position or alignment of the four injections have not been shown to impact on any analgesic effect [18].
Intervention group
Participants randomised to the intervention group will be given SWI using the single injection intradermal technique.
The anatomical site for the single injection will be over the single most painful point as indicated by the woman (Figure 2).
Primary outcome
Decrease in pain measured by VAS at 30 minutes post-intervention.
Secondary outcomes
Secondary outcomes will include:
-
a)
Pain score measured by VAS 10, 60, 90 and 120 mins post-intervention
-
b)
Level of administration discomfort associated with SWI procedure (measured by VAS at 10 minutes post SWI)
-
c)
Subsequent analgesia use (pharmacological and non-pharmacological)
-
d)
Mode of birth
-
e)
Likelihood to use again with subsequent labour
-
f)
Patient satisfaction with analgesic effect
Sample size
A sample size of 133 in each group will be required to achieve 90% power to detect non-inferiority using a one-sided, two-sample t-test. The significance (alpha) of the test is 0.025. The non-inferiority margin is ≤ 1 cm on the VAS and the true difference between the means is assumed to be zero (cms). A standard deviation (SD) of ± 2.5 on the VAS was conservatively estimated from results reported in a recent meta-analysis [6] of SWI studies. As consent and randomisation will occur in the birth suite, attrition is expected to be minimal. However, we have estimated a 20% attrition to account for cases of precipitate birth prior to the assessment of the primary outcome, or other unforseen reasons for withdrawal such as emergency caesarean section. Thus a total of 319 participants will be required.
Recruitment of participants
Trial participation is invited through public antenatal clinics, antenatal education classes and on the Birth Suites at both recruiting hospitals. Although both sites use a number of models of care in the provision of maternity services, all women return to the public antenatal clinic at a particular gestation; 36 weeks and 30 weeks at the Site One and Site Two, respectively. At this time women will be provided with information regarding the trial. The recruitment strategy aims to provide information regarding the trial prior to presentation to the Birth Suite in labour.
Consent
The recruitment strategies are designed to ensure that women receive information regarding SWI as an intervention for back pain and information on the trial, at or before 36 weeks gestation (i.e. prior to inclusion criteria of 37-42 weeks gestation). The majority of women will consent to the trial on presentation to the Birth Suite in labour at both sites. Clinical midwives and/or clinical facilitators from both sites will be available to receive informed consent. A trial investigator will be available via mobile phone to provide support for midwives undertaking consent and enrolment procedures, and to promote continuity of procedures and trial fidelity across the two sites. Women who have been provided with a participant information sheet and indicate an interest in joining the trial will be able to contact the research midwife or investigators for further information or clarification before consent. A video demonstrating the four injection technique is available for women to access at the trial website. http://maternity.mater.org.au/switch. A form will be placed with the woman's chart to highlight that the woman has consented to participate in the study if eligibility criteria is met. Verbal consent will be re-affirmed immediately prior to randomisation and documented within in the woman's clinical chart. Women are able to withdraw consent at any time (i.e. before, during or after the procedure and/or before completing follow-up questionnaire) without affecting their usual clinical care or request alternative and available means of analgesia.
Randomisation
The randomisation schedule for Site One will be prepared by a statistician using a computer-generated list of random numbers. Blinding of allocation to the study intervention will be undertaken using opaque sealed envelopes prepared by Site One administrative staff. A separate randomisation sequence was generated for Site Two in permuted blocks of four to ensure an equal number of participants across both arms of the trial where smaller recruitment numbers are expected. Blinded allocation at this site will be undertaken using similarly prepared opaque sealed envelopes (Figure 3).
Blinding
At both sites, the envelopes will be kept in a locked cupboard on the birth suite and available for randomisation 24 hours/day. The key will be held by the Midwifery Team Leader who will obtain and open one envelope, then with the assistance of another midwife will administer the SWI using the technique detailed within the envelope. The two midwives will be present during the procedure regardless of the SWI technique being administered, to assist with blinding of the procedure to the midwife providing care and collecting data. The injection site(s) will be covered with a hypoallergenic opaque dressing to prevent visualisation of the number of injections used. The participants will be aware not to discuss the type of intervention they were allocated to with their midwife. The midwife caring for the woman will then return to collect the intervention data.
Data collection
Upon randomisation the attending Midwife will document the following data:
Following administration of SWI the following data will be recorded:
-
VAS related to analgesia effect at 10 mins
-
VAS related to discomfort felt during the procedure (at 10 mins)
-
VAS related to analgesic effect at 30 minute intervals up to 2 hours post procedure
At Site One the following data will be extracted from the obstetric database by the research midwife following birth:
The obstetric databases at Site One and Site Two vary slightly in the data items collected. As separate data collection forms have been generated for the randomisation process for Site Two, the data collection forms have been amended to account for any differences in information captured by the database.
The following self-reported data will be sought from the woman within 48 hours following birth:
-
Perceived satisfaction with SWI administration
-
Perceived satisfaction with SWI analgesic benefit
-
Likelihood to use again with subsequent labour
-
Likelihood to recommend to SWI to others
Data will be collected by the Midwife caring for the labouring woman then returned to a securely locked cupboard. Completed data forms will be de-identified and entered into a password protected electronic database. Identified data collection forms will be kept in locked storage for 15 years. Data collection forms at the second site will be stored in a locked cupboard and collected on a fortnightly basis. Data will be entered into a Microsoft Excel spreadsheet and transmitted as a password protected file
Data collection tools
The intrapartum data collection tool has been adapted from an existing document that was used as an audit tool during the introduction of SWI at Site One. For self reported postnatal data, the data collection tool previously published and used in the Australian study by Peart et al. [16] has been made available for use. This tool has been tested for face readability, language and face validity. The instrument will be administered by a researcher blinded to the particular technique used.
Statistical analysis
Demographic and other baseline characteristics will be analysed for comparability between groups to assess the adequacy of randomisation. Differences in VAS pain score between the two groups will be analysed using Student's t-test and analysis of variance (non-parametric tests used if data is highly clustered toward extremes). Data analysis for the primary outcome will determine if the treatment effect lies within the a priori defined non-inferiority margin (± 1 cm) and the null effect (0 cm) at a one-sided alpha of 0.025. The pre-specified non-inferiority margin was based on a one cm (95% CI 0.6-1.4 cm) minimally clinically significant difference reported for VAS in severe pain [14]. The Mann-Whitney U test will be utilised for non-parametric data and chi-squared test for categorical variables. Women who give birth or elect for narcotic and/or regional analgesia after the collection of the primary measure (VAS score 30 minutes post injection) but before the completion of the secondary outcomes (VAS up to 120 mins) will be included in the trial. Women giving birth or electing for narcotic and/or regional anaesthesia prior to the collection of the primary outcome measure will be included in the Intention to Treat (ITT) analysis. The conservative nature of ITT may obscure differences between treatments groups therefore increasing the chance of falsely declaring equivalence [19]. To address this, some authors have recommended that Per Protocol (PP) analysis also be conducted alongside ITT to provide a more robust conclusion if both methods support the non-inferiority [9, 20]. Other authors [21] argue that the benefits of ITT analysis continue to outweigh the PP approach. As it is unlikely that participants in this trial will cross from one intervention to another, the ITT approach will be used unless the dropout out rate exceeds the estimated margin allowed of 20%. Should the dropout rate exceed 20% then a PP analysis will also be conducted. Figure 4 outlines possible scenarios for the outcome of the data analysis based on the pre-defined noninferiority margin, indicated as the shaded area. Error bars indicate 90% confidence intervals (CI). If the CI is completely to the left of zero, the treatment is inferior (scenario A). Scenarios C,D and E indicate noninferiority as the CI lies within the specified margin (shaded area). Scenario F would indicate superiority. An inconclusive result (scenario B) is unlikely as the sample size is sufficiently powered to provide a result [22].
In the event that women experience no relief from the single injection and request the four injection technique, these women will remain within the study, and the data will be analysed according to ITT and per protocol principles.
Women requesting a repeat injection will receive the standard four injection technique. A pre-injection VAS score will be sought prior to administration and post injection VAS score will be collected at 30 minutes. These will be reported separately.
Confidentiality and data security
The data is de-identified, coded and entered onto a password protected database.
Data safety monitoring board
A Data Safety Monitoring Board has not been established for this trial. As there have been no adverse events reported in any previous trial on the topic, the trial was considered to be low risk. However, a senior obstetrician at both sites has agreed to act as a clinical monitor to investigate any adverse events that may be associated with the trial. This process has been approved by the Human Research Ethics Committee at each site.
Project management
Project management will be overseen by the research team that consists of midwifery and obstetric clinicians, midwifery academics and researchers from both sites. The research team will meet regularly during the projects development phase and regular contact and progress reports maintained via email during the recruitment phase of the trial.
Ethical issues
Human Research Ethics Committee (HREC) Approval
Mater Health Services HREC No:1422M
Australian Catholic University HREC No:Q2009 48
Royal Brisbane and Women's Hospital HREC No:HREC/10/QRBW/155
Women of Non-English Speaking Backgrounds (NESB) and minors
At both sites, an onsite interpreter service is available during "office hours" for the most common language groups of Vietnamese and Mandarin/Cantonese with contract interpreters for eighteen other languages available. At other times the Birth Suite accesses a telephone interpreter service. For NESB women considering SWI as an intervention for back pain, the interpreter service accessed at the time will be utilised to provide information and gain consent for inclusion in the trial. To supplement this, copies of the Participant Information Sheet and consent form will be available in Vietnamese and Mandarin/Cantonese. In the event that a suitable interpreter cannot be found, inclusion in the trial will not be offered. Postnatal data will be collected using this method as interpreters are required when providing routine postnatal information.
Potential risks
The four injection SWI technique is routinely used in the birth suites at Site One. Therefore, no additional risks from study participation would be expected. Moreover, no allergic or systemic reactions to the procedure have been reported in the literature other than the brief stinging sensation immediately following administration [5].
